Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for undersntading the complexity of pathway activation

Current Genomics

Volumn 9, Issue 5, 2008, Pages 349-360

  Itadani, Hiraku ^a   Mizuarai, Shinji ^a   Kotani, Hidehito ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cancer therapy; Drug discovery; Expression signature; Signaling pathway; Systems biology

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; B RAF KINASE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA SECRETASE; INTERFERON; K RAS PROTEIN; MYC PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA;

CANCER CLASSIFICATION; CANCER STAGING; CARCINOGENESIS; CELL CYCLE PROGRESSION; COMPUTER SIMULATION; DISEASE COURSE; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HIGH THROUGHPUT SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PROGNOSIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 49749114386     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920208785133235     Document Type: Review

References (82)

1. Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100: 57-70.
2. Parsons, D.W., Wang, T.L., Samuels, Y., Bardelli, A., Cummins, J.M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J.K.V., Markowitz, S., Kinzler, K., Vogelstein, B., Lengauer, C., Velculescu, V.E. Colorectal cancer - Mutations in a signalling pathway. Nature 2005, 436: 792.
3. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P.A., Kaminker, J.S., Zhang, Z.M., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J.K.V., Sukumar, S., Polyak, K., Park, B.H., Pethiyagoda, C.L., Pant, P.V.K., Ballinger, D.G., Sparks, A.B., Hartigan, J., Smith, D.R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S.D., Parmigiani, G., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318: 1108-1113.
4. Greenman, C., Stephens P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E.E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D.P., Louis, D.N., Goldstraw, P., Nicholson, A.G., Brasseur, F., Looijenga, L., Weber, B.L., Chiew, Y.E., Defazio, A., Greaves, M.F., Green, A.R., Campbell, P., Birney, E., Easton, D.F., Chenevix-Trench, G., Tan, M.H., Khoo, S.K., Teh, B.T., Yuen, S.T., Leung, S.Y., Wooster, R., Futreal, P.A., Stratton, M.R. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446: 153-158.
5. Thomas, R.K., Baker, A.C., DeBiasi, R.M., Winckler, W., La-Framboise, T., Lin, W.M., Wang, M., Feng, W., Zander, T., Mac-Connaill, L.E., Lee, J.C., Nicoletti, R., Hatton, C., Goyette, M., Girard, L., Majmudar, K., Ziaugra, L., Wong, K.K., Gabriel, S., Beroukhim, R., Peyton, M., Barretina, J., Dutt, A., Emery, C., Greulich, H., Shah, K., Sasaki, H., Gazdar, A., Minna, J., Armstrong, S.A., Mellinghoff, I.K., Hodi, F.S., Dranoff, G., Mischel, P.S., Cloughesy, T.F., Nelson, S.F., Liau, L.M., Mertz, K., Rubin, M.A., Moch, H., Loda, M., Catalona, W., Fletcher, J., Signoretti, S., Kaye, F., Anderson, K.C., Demetri, G.D., Dummer, R., Wagner, S., Herlyn, M., Sellers, W.R., Meyerson, M., Garraway, L.A. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007, 39: 347-351.
6. Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S.D., Willis, J., Dawson, D., Willson, J.K.V., Gazdar, A.F., Hartigan, J., Wu, L., Liu, C.S., Parmigiani, G., Park, B.H., Bachman, K.E., Papadopoulos, N., Vogelstein, B., Kinzler, K.W., Velculescu, V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314: 268-274.
7. Baker, M. In biomarkers we trust? Nat. Biotechnol. 2005, 23: 297-304.
8. Storey, J.D., Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 2003, 100: 9440-9445.
9. Zeeberg, B.R., Feng, W.M., Wang, G., Wang, M.D., Fojo, A.T., Sunshine, M., Narasimhan, S., Kane, D.W., Reinhold, W.C., Lababidi, S., Bussey, K.J., Riss, J., Barrett, J.C., Weinstein, J.N. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003, 4: R28
10. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102: 15545-15550.
11. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., Houstis, N., Daly, M.J., Patterson, N., Mesirov, J.P., Golub, T.R., Tamayo, P., Spiegelman, B., Lander, E.S., Hirschhorn, J.N., Altshuler, D., Groop, L.C. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34: 267-273.
12. Mayburd, A.L., Martinez, A., Sackett, D., Liu, H.T., Shih, J., Tauler, J., Avis, I., Mulshine, J.L. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clin. Cancer Res. 2006, 12: 1820-1827.
13. Nikolsky, Y., Ekins, S., Nikolskaya, T., Bugrim, A. A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol. Lett. 2005, 158: 20-29.
14. Werner, T. Bioinformatics applications for pathway analysis of microarray data. Curr. Opin. Biotechnol. 2008, 19: 50-54.
15. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C.J., Marais, R. B-V599E-RAF is an oncogene in melanocytes. Cancer Res. 2004, 64: 2338-2342.
16. Calipel, A., Lefevre, G., Pouponnot, C., Mouriaux, F., Eychene, A., Mascarelli, F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J. Biol. Chem. 2003, 278: 42409-42418.
17. Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P.M., Walker, G.J., Boyle, G.M., Harper, U., Cozzi, S.J., Hansen, K., Yudt, L., Schmidt, C., Hersey, P., Ellem, K.A.O., O'Rourke, M.G.E., Parsons, P.G., Meltzer, P., Ringner, M., Hayward, N.K. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004, 23: 4060-4067.
18. Ryan, K.M., Phillips, A.C., Vousden, K.H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 2001, 13: 332-337.
19. May, P., May, E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999, 18: 7621-7636.
20. Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E.T., Bergh, J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102: 13550-13555.
21. Saal, L.H. Johansson, P., Holm, K., Gruvberger-Saal, S.K., She, Q.B., Maurer, M., Koujak, S., Ferrando, A.A., Malmstrom, P., Memeo, L., Isola, J., Bendahl, P.O., Rosen, N., Hibshoosh, H., Ringner, M., Borg, A., Parsons, R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. USA 2007, 104: 7564-7569.
22. Mehrian-Shai, R., Chen, C.D., Shi, T., Horvath, S., Nelson, S.F., Reichardt, J.K.V., Sawyers, C.L. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K-Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl. Acad. Sci. USA 2007, 104: 5563-5568.
23. Tureci, O., Ding, J.Y., Hilton, H., Bian, H.J., Ohkawa, H., Braxenthaler, M., Seitz, G., Raddrizzani, L., Friess, H., Buchler, M., Sahin, U., Hammer, J. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. FASEB J. 2003, 17: 376-385.
24. Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P.A., Stratton, M.R. Cosmic 2005. Br. J. Cancer 2006, 94: 318-322.
25. Choi, K., Creighton, C.J., Stivers, D., Fujimoto, N., Kurie, J.M. Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations. PLoS ONE 2007, 2: e1226.
26. Mounawar, M., Mukeria, A., Le Calvez, F., Hung, R.J., Renard, H., Cortot, A., Bollart, C., Zaridze, D., Brennan, P., Boffetta, P., Brambilla, E., Hainaut, P. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14(arf) expression in non-small cell lung cancers in relation to smoking history. Cancer Res. 2007, 67: 5667-5672.
27. Frese, K.K., Tuveson, D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7: 645-658.
28. Mayhew, C.N., Carter, S.L., Fox, S.R., Sexton, C.R., Reed, C.A., Srinivasaw, S.V., Liu, X.D., Wikenheiser-Brokamp, K., Boivin, G.P., Lee, J.S., Aronow, B.J., Thorgersson, S.S., Knudsen, E.S. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 2007, 133: 976-984.
29. Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J.J., Ladd-Acosta, C., Mesirov, J., Golub, T.R., Jacks, T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 2005, 37: 48-55.
30. Van Der Flier, L.G., Sabates-Bellver, J., Oving, I., Haegebarth, A., De Palo, M., Anti, M., Van Gijn, M.E., Suijkerbuijk, S., van de Wetering, M., Marra, G., Clevers, H. The intestinal Wnt TCF signature. Gastroenterology 2007, 132: 628-632.
31. Troester, M.A., Herschkowitz, J.I., Oh, D.S., He, X.P., Hoadley, K.A., Barbier, C.S., Perou, C.M. Gene expression patterns-associated with p53 status in breast cancer. BMC Cancer 2006, 6: 276
32. Gazel, A., Banno, T., Walsh, R., Blumenberg, M. Inhibition of JNK promotes differentiation of epidermal keratinocytes. J. Biol. Chem. 2006, 281: 20530-20541.
33. Palomero, T., Lim, W.K., Odom, D.T., Sulis, M.L., Real, P.J., Margolin, A., Barnes, K.C., O'Neil, J., Neuberg, D., Weng, A.P., Aster, J.C., Sigaux, F., Soulier, J., Look, A.T., Young, R.A., Califano, A., Ferrando, A.A. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103: 18261-18266.
34. Scandura, J.M., Boccuni, P., Massague, J., Nimer, S.D. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc. Natl. Acad. Sci. USA 2004, 101: 15231-15236.
35. Creighton, C.J., Hilger, A.M., Murthy, S., Rae, J.M., Chinnaiyan, A.M., El Ashry, D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006, 66: 3903-3911.
36. Bild, A.H., Yao, G., Chang, J.T., Wang, Q.L., Potti, A., Chasse, D., Joshi, M.B., Harpole, D., Lancaster, J.M., Berchuck, A., Olson, J.A., Marks, J.R., Dressman, H.K., West, M., Nevins, J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439: 353-357.
37. Potti, A., Dressman, H.K., Bild, A., Riedel, R.F., Chan, G., Sayer, R., Cragun, J., Cottrill, H., Kelley, M.J., Petersen, R., Harpole, D., Marks, J., Berchuck, A., Ginsburg, G.S., Febbo, P., Lancaster, J., Nevins, J.R. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006, 12: 1294-1300.
38. Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M., Manola, J., Brugarolas, J., McDonnell, T.J., Golub, T.R., Loda, M., Lane, H.A., Sellers, W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med 2004, 10: 594-601.
39. Creighton, C.J. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007, 26: 4648-4655.
40. van't Veer, L.J., Dai, H.Y., van de Vijver, M.I., He, Y.D.D., Hart, A.A.M., Mao, M., Peterse, H.L., van der Kooy, K., Marton, M.J., Witteveen, A.T., Schreiber, G.J., Kerkhoven, R.M., Roberts, C., Linsley, P.S., Bernards, R., Friend, S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415: 530-536.
41. West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., Zuzan, H., Olson, J.A., Marks, J.R., Nevins, J.R. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci USA 2001, 98: 11462-11467.
42. Lawlor, E.R., Soucek, L., Brown-Swigart, L., Shchors, K., Bialucha, C.U., Evan, G.I. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res. 2006, 66: 4591-4601.
43. O'Reilly, K.E., Rojo, F., She, Q.B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hofmann, F., Hicklin, D.J., Ludwig, D.L., Baselga, J., Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66: 1500-1508.
44. Kim, M.J., Lee, J.H., Koh, H.J., Lee, S.Y., Jang, C.S., Chung, C.J., Sung, J.H., Blenis, J., Chung, J.K. Inhibition of ERK-MAP kinase signaling by RSK during Drosophila development. EMBO J. 2006, 25: 3056-3067.
45. Amit, I., Citri, A., Shay, T., Lu, Y.L., Katz, M., Zhang, F., Tarcic, G., Siwak, D., Lahad, J., Jacob-Hirsch, J., Amariglio, N., Vaisman, N., Segal, E., Rechavi, G., Alon, U., Mills, G.B., Domany, E., Yarden, Y. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 2007, 39: 503-512.
46. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350: 2129-2139.
47. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304: 1497-1500.
48. Massarelli, E., Varella-Garcia, M., Tang, X.M., Xavier, A.C., Ozburn, N.C., Liu, D.D., Bekele, B.N., Herbst, R.S., Wistuba, I.I. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2007, 13: 2890-2896.
49. Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Wong, T.W., Huang, X., Takimoto, C.H., Godwin, A.K., Tan, B.R., Krishnamurthi, S.S., Burris, H.A., Poplin, E.A., Hidalgo, M., Baselga, J., Clark, E.A., Mauro, D.J. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25: 3230-3237.
50. Berns, K., Horlings, H.M., Hennessy, B.T., Madiredjo, M., Hijmans, E.M., Beelen, K., Linn, S.C., Gonzalez-Angulo, A.M., Stemke-Hale, K., Hauptmann, M., Beijersbergen, R.L., Mills, G.B., de Vijver, M.J.V., Bernards, R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12: 395-402.
51. Mellinghoff, I.K., Cloughesy, T.F., Mischel, P.S. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 2007, 13: 378-381.
52. Bos, J.L. Ras Oncogenes in Human Cancer - A Review. Cancer Res. 1989, 49: 4682-4689.
53. Mercer, K.E., Pritchard, C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta - Rev. Cancer 2003, 1653: 25-40.
54. Kim, I.J., Kang, H.C., Jang, S.G., Kim, K., Ahn, S.A., Yoon, H.J., Yoon,, S.N., Park, J.G. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. Carcinogenesis 2006 27: 392-404.
55. Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., Reinhold, W.C., Myers, T.G., Andrews, D.T., Scudiero, D.A., Eisen, M.B., Sausville, E.A., Pommier, Y., Botstein, D., Brown, P.O., Weinstein, J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24: 236-244.
56. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.P., Subramanian, A., Ross, K.N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S.A., Haggarty, S.J., Clemons, P.A., Weij R., Carr, S.A., Lander, E.S., Golub, T.R. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313: 1929-1935.
57. Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R.W., Opferman, J.T., Sallan, S.E., den Boer, M.L., Pieters, R., Golub, T.R., Armstrong, S.A. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10: 331-342.
58. Hieronymus, H., Lamb, J., Ross, K.N., Peng, X.P., Clement, C., Rodina, A., Nieto, M., Du, J.Y., Stegmaier, K., Raj, S.M., Maloney, K.N., Clardy, J., Hahn, W.C., Chiosis, G., Golub, T.R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10: 321-330.
59. Goss, V.L., Lee, K.A., Moritz, A., Nardone, J., Spek, E.J., MacNeill, J., Rush, J., Comb, M.J., Polakiewicz, R.D. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 2006, 107: 4888-4897.
60. MacBeath, G., Schreiber, S.L. Printing proteins as microarrays for high-throughput function determination. Science 2000, 289: 1760-1763.
61. Robinson, W.H., DiGennaro, C., Hueber, W., Haab, B.B., Kamachi, M., Dean, E.J., Fournel, S., Fong, D., Genovese, M.C., de Vegvar, H.E.N., Skriner, K., Hirschberg, D.L., Morris, R.I., Muller, S., Pruijn, G.J., van Venrooij, W.J., Smolen, J.S., Brown, P.O., Steinman, L., Utz, P.J. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. 2002, 8: 295-301.
62. Hall, D.A., Zhu, H., Zhu, X.W., Royce, T., Gerstein, M., Snyder, M. Regulation of gene expression by a metabolic enzyme. Science 2004, 306: 482-484.
63. Jones, R.B., Gordus, A., Krall, J.A., MacBeath, G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006, 439: 168-174.
64. Sasagawa, S., Ozaki, Y., Fujita, K., Kuroda, S. Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat. Cell Biol. 2005, 7: 365-U31.
65. Hoadley, K.A., Weigman, V.J., Fan, C., Sawyer, L.R., He, X.P., Troester, M.A., Sartor, C.I., Rieger-House, T., Bernard, P.S., Carey, L.A., Perou, C.M. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007, 8: 258
66. Matsushima-Nishiu, M., Unoki, M., Ono, K., Tsunoda, T., Minaguchi, T., Kuramoto, H., Nishida, M., Satoh, T., Tanaka, T., Nakamura, Y. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res. 2001, 61: 3741-3749.
67. He, X.C., Yin, T., Grindley, J.C., Tian, Q., Sato, T., Tao, W.A., Dirisina, R., Porter-Westpfahl, K.S., Hembree, M., Johnson, T., Wiedemann, L.M., Barrett, T.A., Hood, L., Wu, H., Li, L.H. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat. Genet. 2007, 39: 189-198.
68. Ellwood-Yen, K., Graeber, T.G., Wongvipat, J., Iruela-Arispe, M.L., Zhang, J.F., Matusik, R., Thomas, G.V., Sawyers, C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4: 223-238.
69. O'Neil, J., Grim, J., Strack, P., Rao, S., Tibbitts, D., Winter, C., Hardwick, J., Welcker, M., Meijerink, J.P., Pieters, R., Draetta, G., Sears, R., Clurman, B.E, Look, A.T. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 2007, 204: 1813-1824.
70. Dohda, T., Maljukova, A., Liu, L., Heyman, M., Grander, D., Brodin, D., Sangfelt, O., Lendahl, U. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp. Cell Res. 2007, 313: 3141-3152.
71. Black, E.P., Huang, E., Dressman, H., Rempel, R., Laakso, N., Asa, S.L., Ishida, S., West M., Nevins, J.R. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res. 2003, 63: 3716-3723.
72. Muller, H., Bracken, A.P., Vernell, R., Moroni, M.C., Christians, F., Grassilli, E., Prosperini, E., Vigo, E., Oliner, J.D., Helin, K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001, 15: 267-285.
73. Ishida, S., Huang, E., Zuzan, H., Spang, R., Leone, G., West, M., Nevins, J.R. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol. Cell. Biol. 2001, 21: 4684-4699.
74. Polager, S., Kalma, Y., Berkovich, E., Ginsberg, D. E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 2002, 21: 437-446.
75. Wu, K.M., Yang, Y., Wang, C.G., Davoli, M.A., D'Amico, M., Li, A.P., Cveklova, K., Kozmik, Z., Lisanti, M.P., Russell, R.G., Cvekl, A., Pestell, R.G. DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J. Biol. Chem. 2003, 278: 51673-51684.
76. Ranganathan, P., Agrawal, A., Bhushan, R., Chavalmane, A.K., Kalathur, R.K.R., Takahashi, T., Kondaiah, P. Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells. BMC Genomics 2007, 8: 98
77. Silva-Vargas, V., Lo Celso, C., Giangreco, A., Ofstad, T., Prowse, D.M., Braun, K.M., Watt, F.M. beta-catenin and hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells. Dev. Cell 2005, 9: 121-131.
78. Fevr, T., Robine, S., Louvard, D., Huelsken, J. Wnt/beta-Catenin is essential for intestinal Homeostasis and maintenance of intestinal stem cells. Mol. Cell. Biol. 2007, 27: 7551-7559.
79. Eichberger, T., Sander, V., Schnidar, H., Regl, G., Kasper, M., Schmid, C., Plamberger, S., Kaser, A., Aberger, F., Frischauf, A.M. Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. Genomics 2006, 87: 616-632.
80. Elkon, R., Rashi-Elkeles, S., Lerenthal, Y., Linhart, C., Tenne, T., Amariglio, N., Rechavi, G., Shamir, R., Shiloh, Y. Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis. Genome Biol. 2005, 6: R43
81. Baechler, E.C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., Ortmann, W.A., Espe, K.J., Shark, K.B., Grande, W.J., Hughes, K.M., Kapur, V., Gregersen, P.K., Behrens, T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003, 100: 2610-2615.
82. Blum, R., Elkon, R., Yaari, S., Zundelevich, A., Jacob-Hirsch, J., Rechavi, G., Shamir, R., Kloog, Y. Gene expression signature of human cancer cell lines treated with the Ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007, 67: 3320-3328.